{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:11:48Z","timestamp":1790712708453,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T00:00:00Z","timestamp":1316476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the safety profile of eight oral nonsteroidal anti\u2010inflammatory drugs (NSAIDs) available in France, using data reported through the French pharmacovigilance system. Data (from 2002 to 2006) were analysed for aceclofenac, diclofenac, ketoprofen, meloxicam, naproxen, nimesulide, piroxicam and tenoxicam, focusing on the reported rates of serious adverse drug reactions (ADRs) in the following system organ classes: gastrointestinal, hepatic, cutaneous, renal and cardiovascular. A total of 42\u2003389 serious ADR reports were identified, and 38\u2003506 were included in a case\/noncase analysis. Ketoprofen was associated with the highest cumulative reported rate of serious ADRs (0.78 cases per million defined daily doses), followed by diclofenac (0.58), nimesulide (0.52), naproxen (0.50), piroxicam (0.47), tenoxicam (0.42), meloxicam (0.41) and aceclofenac (0.30). The most frequently reported serious ADRs were cutaneous, followed by gastrointestinal, hepatic, renal and rarely, cardiovascular events. In the case\/noncase analysis, ketoprofen, piroxicam and naproxen were associated with the highest risk of serious gastrointestinal ADRs (odds ratios [ORs] of 6.87, 6.54 and 5.07, respectively). Nimesulide and aceclofenac were associated with the highest risk of liver ADRs (adjusted ORs of 4.53 and 3.67, respectively), as was meloxicam for cutaneous ADRs (adjusted OR of 3.15) and tenoxicam for renal ADRs (adjusted OR of 3.17). The most frequent serious ADRs reported with the selected oral NSAIDs are cutaneous, followed by gastrointestinal, hepatic and renal events. The highest risks for serious gastrointestinal, hepatic, cutaneous and renal adverse events were linked, respectively, with ketoprofen, nimesulide, meloxicam and tenoxicam compared with the other NSAIDs.<\/jats:p>","DOI":"10.1111\/j.1472-8206.2011.00991.x","type":"journal-article","created":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T12:28:01Z","timestamp":1316521681000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Adverse drug reactions associated with the use of NSAIDs: a case\/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002\u20132006"],"prefix":"10.1111","volume":"27","author":[{"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Grolleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Association Fran\u00e7aise des Centres R\u00e9gionaux de Pharmacovigilance (CRPV)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,20]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.1.33"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2093"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520701192326"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00370-8"},{"key":"e_1_2_8_6_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archinte.1994.00420030117012","article-title":"Acute liver injury associated with nonsteroidal anti\u2010inflammatory drugs and the role of risk factors","volume":"154","author":"Garcia Rodriguez L.A.","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/j.1875-9114.1997.tb03747.x","article-title":"A review of epidemiologic research on drug\u2010induced acute liver injury using the general practice research data base in the United Kingdom","volume":"17","author":"Garcia Rodriguez L.A.","year":"1997","journal-title":"Pharmacotherapy"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6858.865"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.6.673"},{"key":"e_1_2_8_10_2","unstructured":"European Medicine Agency EMA Press Release EMEA\/247323\/2005 \u201cGeneral reccomendation about NSAIDs.\u201dhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500014477.pdf(accessed 16 February 2011)."},{"key":"e_1_2_8_11_2","unstructured":"National Institute for Clinical Excellence.Guidance on the use of cyclo\u2010oxygenase (Cox) II selective inhibitors celecoxib rofecoxib meloxicam and etodolac for osteoarthritis and rheumatoid arthritis.National Institute of Clinical Excellence London 2001; Technology Appraisal Guidance No. 27."},{"issue":"1","key":"e_1_2_8_12_2","first-page":"S29","article-title":"Do selective cyclo\u2010oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti\u2010inflammatory drug therapy?","volume":"14","author":"Deviere J.","year":"2002","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.11.1859"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427070-00002"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0497-3"},{"key":"e_1_2_8_16_2","first-page":"59","article-title":"Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups","volume":"15","author":"Solomon D.H.","year":"2008","journal-title":"Arthritis Rheum."},{"key":"e_1_2_8_17_2","unstructured":"Code de la Sant\u00e9 Publique Article R5121\u2010153 version en vigueur au 8 aout 2004.http:\/\/www.legifrance.gouv.fr\/(accessed 16 February 2011)."},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0813-5"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2006.00416.x"},{"key":"e_1_2_8_21_2","first-page":"2234","article-title":"The risk of Stevens\u2010Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective","volume":"30","author":"Mockenhaupt M.","year":"2003","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427060-00005"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7405.18"},{"key":"e_1_2_8_24_2","first-page":"596","article-title":"Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System","volume":"72","author":"Macia M.A.","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_8_25_2","unstructured":"European Medicine Agency.2004.EMEA statement following withdrawal of nimesulide from the Spanish market. EMEA\/CPMP\/1724\/04\/2004. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Nimesulide_31\/WC500013818.pdf(accessed 16 February 2011)."},{"key":"e_1_2_8_26_2","unstructured":"National Agency for Medicine (Finland).NAM statement following withdrawal of Nimed (nimesulide) from the Finnish market. Available from:http:\/\/www.fimea.fi\/whats_new\/news\/1\/0\/the_sale_of_nimed_an_anti\u2010inflammatory_analgesic_is_temporarily_suspended_due_to_its_adverse_liver_effects(accessed 16 February 2011)."},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2007.3.2.225"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.08.014"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1472-8206.2011.00991.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1472-8206.2011.00991.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:17:23Z","timestamp":1698650243000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1472-8206.2011.00991.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,20]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/j.1472-8206.2011.00991.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1472-8206.2011.00991.x","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,20]]},"assertion":[{"value":"2011-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}